Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.0
4.5
Journals
Cancers
Special Issues
Ovarian Cancer Proliferation and Progression
share announcement

Ovarian Cancer Proliferation and Progression

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Biomarkers".

Deadline for manuscript submissions: closed (20 June 2024) | Viewed by 2869

Special Issue Editors

Dr. Anchal Sharma

E-Mail
Guest Editor
Advanced Analytics and Data Sciences, Eli Lilly and Company, New York, NY, USA
Interests: single cell technology; immune oncology; cancer computational biology; machine learning; immunology
Dr. Kübra Karagöz

E-Mail
Guest Editor
Translational Data Science, Genmab, Princeton, NJ, USA
Interests: cancer research; computational biology; precision medicine; clinical statistics

Special Issue Information

Dear Colleagues, 

Ovarian cancer is one of the leading causes of death in women diagnosed with gynecological cancers. In most cases, it goes unnoticed until an advanced stage is reached, thereby leading to poor outcomes of the disease. Ovarian cancers comprise of different subtypes, such as epithelial, germ cell and stromal cell tumors, each differing in their etiologies and progression rates. Better understanding of this heterogeneous group of malignancies and design of new therapies warrant further research. In this Special Issue of Cancers, experts in this field will review the current advances in ovarian cancers with a special focus on proliferation and progression.

Dr. Anchal Sharma
Dr. Kübra Karagöz
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • ovarian cancer
  • single cell RNA-Seq
  • genomics
  • transcriptomics
  • proteomics
  • biomarker
  • drug target

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

12 pages, 2532 KiB  
Article
The Prognosis Predictive Score around Neo Adjuvant Chemotherapy (PPSN) Improves Diagnostic Efficacy in Predicting the Prognosis of Epithelial Ovarian Cancer Patients
by Naoki Kawahara, Shoichiro Yamanaka, Sumire Sugimoto, Junya Kamibayashi, Kyohei Nishikawa, Ryuji Kawaguchi and Fuminori Kimura
Cancers 2023, 15(20), 5062; https://doi.org/10.3390/cancers15205062 - 19 Oct 2023
Cited by 1 | Viewed by 1038
Abstract
Background: Recent studies have shown that pretreatment inflammatory responses can predict prognosis. However, no reports have analyzed the combined effect of the inflammatory response with pre-treatment and post-neo adjuvant chemotherapy (NACT). This retrospective study aims to identify factors predicting prognosis and create a [...] Read more.
Background: Recent studies have shown that pretreatment inflammatory responses can predict prognosis. However, no reports have analyzed the combined effect of the inflammatory response with pre-treatment and post-neo adjuvant chemotherapy (NACT). This retrospective study aims to identify factors predicting prognosis and create a novel predictive scoring system. Methods: The study was conducted at our institution between June 2006 and March 2020. Demographic and clinicopathological data were collected from patients with advanced epithelial ovarian cancer who underwent neoadjuvant chemotherapy after sample collection by laparoscopic or laparotomy surgery, followed by interval debulking surgery. We created a scoring system, called the Predictive Prognosis Score around NACT (PPSN), using factors extracted from a receiver operating characteristic curve analysis. Univariate and multivariate analyses were conducted to assess the efficacy of PPSN in predicting progression-free survival and overall survival. Kaplan-Meier and log-rank tests were used to compare the PFS or OS rate. Results: Our study included 72 patients, with a cut-off value of four for the scoring system. Our analysis showed that high PPSN (≥4) significantly predicts poor prognosis. Moreover, CD3+ and CD8+ tumor-infiltrating lymphocytes with low PPSN (<4) showed higher aggregation than those with high PPSN (≥4) cases. Conclusion: Our study shows that PPSN could be a useful prognostic tool for advanced EOC patients who undergo NACT followed by IDS. Full article
(This article belongs to the Special Issue Ovarian Cancer Proliferation and Progression)
►▼ Show Figures

Figure 1

Review

Jump to: Research

22 pages, 1245 KiB  
Review
A Recipe for Successful Metastasis: Transition and Migratory Modes of Ovarian Cancer Cells
by Aleksandra Śliwa, Anna Szczerba, Paweł Piotr Pięta, Piotr Białas, Jakub Lorek, Ewa Nowak-Markwitz and Anna Jankowska
Cancers 2024, 16(4), 783; https://doi.org/10.3390/cancers16040783 - 15 Feb 2024
Viewed by 1333
Abstract
One of the characteristic features of ovarian cancer is its early dissemination. Metastasis and the invasiveness of ovarian cancer are strongly dependent on the phenotypical and molecular determinants of cancer cells. Invasive cancer cells, circulating tumor cells, and cancer stem cells, which are [...] Read more.
One of the characteristic features of ovarian cancer is its early dissemination. Metastasis and the invasiveness of ovarian cancer are strongly dependent on the phenotypical and molecular determinants of cancer cells. Invasive cancer cells, circulating tumor cells, and cancer stem cells, which are responsible for the metastatic process, may all undergo different modes of transition, giving rise to mesenchymal, amoeboid, and redifferentiated epithelial cells. Such variability is the result of the changing needs of cancer cells, which strive to survive and colonize new organs. This would not be possible if not for the variety of migration modes adopted by the transformed cells. The most common type of metastasis in ovarian cancer is dissemination through the transcoelomic route, but transitions in ovarian cancer cells contribute greatly to hematogenous and lymphatic dissemination. This review aims to outline the transition modes of ovarian cancer cells and discuss the migratory capabilities of those cells in light of the known ovarian cancer metastasis routes. Full article
(This article belongs to the Special Issue Ovarian Cancer Proliferation and Progression)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop